{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T11:20:40Z","timestamp":1773832840657,"version":"3.50.1"},"reference-count":27,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"10","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2009,5,27]]},"abstract":"<jats:sec>\n                    <jats:title>Background.<\/jats:title>\n                    <jats:p>Retrospective comparison of treatment-related kidney transplant outcomes may be facilitated by multivariable statistical adjustments and case-matching.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods.<\/jats:title>\n                    <jats:p>We studied Organ Procurement and Transplantation Network registry data for kidney transplants in 2001 to 2005 managed with thymoglobulin, basiliximab, or no antibody induction and discharge maintenance immunosuppression regimens of tacrolimus and mycophenolate mofetil. The primary outcome was the 6 month, Food and Drug Administration-approved composite endpoint of rejection, graft failure, or death. Outcomes according to induction exposure were compared using logistic regression analysis, exposure likelihood matching, and outcome risk score matching.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results.<\/jats:title>\n                    <jats:p>All statistical approaches demonstrated lower rates of the 6-month triple endpoint with thymoglobulin compared with basiliximab when steroids were present, with approximately 22% adjusted, relative reduction by logistic regression analysis and 3% absolute reductions by matching approaches. When steroids were absent, risk reduction among thymoglobulin versus basiliximab-treated patients was of larger magnitude but borderline statistical significance. Triple endpoint incidence was lower with both induction regimens compared with no induction across methods. Estimated sample sizes necessary to detect the observed differences between induction types in the presence of steroids in a prospective trial ranged from 1600 to nearly 7000 patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions.<\/jats:title>\n                    <jats:p>Consistency across statistical approaches suggests superiority of thymoglobulin compared with basiliximab or no antibody induction therapy for 6-month kidney transplant outcomes in the modern immunosuppression era. As the sample sizes necessary to power a prospective superiority trial are likely prohibitive, studies such as these provide clinically relevant information that may not be otherwise attainable.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/tp.0b013e3181a484d7","type":"journal-article","created":{"date-parts":[[2009,5,21]],"date-time":"2009-05-21T17:18:37Z","timestamp":1242926317000},"page":"1520-1529","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":46,"title":["Early Outcomes of Thymoglobulin and Basiliximab Induction in Kidney Transplantation"],"prefix":"10.1097","volume":"87","author":[{"given":"Lisa M.","family":"Willoughby","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark A.","family":"Schnitzler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel C.","family":"Brennan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brett W.","family":"Pinsky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nino","family":"Dzebisashvili","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paula M.","family":"Buchanan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luca","family":"Neri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisa A.","family":"Rocca-Rey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kevin C.","family":"Abbott","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Krista L.","family":"Lentine","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-14-20260130","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1016\/j.transproceed.2004.03.084","article-title":"Induction versus noninduction therapy in kidney transplantation: Considering different PRA levels and different induction therapies","volume":"36","author":"Castro","year":"2004","journal-title":"Transplant Proc"},{"key":"R2-14-20260130","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1097\/01.TP.0000100826.58738.2B","article-title":"Association of the type of induction immunosuppression with posttransplant lymphoproliferative disorder, graft survival, and patient survival after primary kidney transplantation [see comment]","volume":"76","author":"Cherikh","year":"2003","journal-title":"Transplantation"},{"key":"R4-14-20260130","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.1056\/NEJMoa060068","article-title":"Rabbit antithymocyte globulin versus basiliximab in renal transplantation [see comment]","volume":"355","author":"Brennan","year":"2006","journal-title":"N Eng J Med"},{"key":"R5-14-20260130","doi-asserted-by":"crossref","first-page":"1832","DOI":"10.1111\/j.1600-6143.2007.01860.x","article-title":"Efficacy of anti-IL-2 receptor antibodies compared to no induction and to antilymphocyte antibodies in renal transplantation","volume":"7","author":"Patlolla","year":"2007","journal-title":"Am J Transplant"},{"key":"R6-14-20260130","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1034\/j.1600-6143.2002.020109.x","article-title":"Immunoprophylaxis with basiliximab compared with antithymocyte globulin in renal transplant patients receiving MMF-containing triple therapy","volume":"2","author":"Lebranchu","year":"2002","journal-title":"Am J Transplant"},{"key":"R7-14-20260130","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1097\/01.TP.0000129812.68794.CC","article-title":"Sequential protocols using basiliximab versus antithymocyte globulins in renal-transplant patients receiving mycophenolate mofetil and steroids","volume":"78","author":"Mourad","year":"2004","journal-title":"Transplantation"},{"key":"R8-14-20260130","doi-asserted-by":"crossref","first-page":"2298","DOI":"10.1016\/j.transproceed.2006.06.133","article-title":"Long-term results of monoclonal anti-Il2-receptor antibody versus polyclonal antilymphocyte antibodies as induction therapy in renal transplantation","volume":"38","author":"Al Najjar","year":"2006","journal-title":"Transplant Proc"},{"key":"R9-14-20260130","doi-asserted-by":"crossref","first-page":"2562","DOI":"10.1056\/NEJMoa067411","article-title":"Reduced exposure to calcineurin inhibitors in renal transplantation","volume":"357","author":"Ekberg","year":"2007","journal-title":"N Engl J Med"},{"key":"R10-14-20260130","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1097\/01.TP.0000056635.59888.EF","article-title":"A three-arm study comparing immediate tacrolimus therapy with antithymocyte globulin induction therapy followed by tacrolimus or cyclosporine A in adult renal transplant recipients","volume":"75","author":"Charpentier","year":"2003","journal-title":"Transplantation"},{"key":"R11-14-20260130","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1080\/01621459.1989.10478868","article-title":"Optimal matching for observational studies","volume":"84","author":"Rosenbaum","year":"1989","journal-title":"J Am Stat Assoc"},{"key":"R12-14-20260130","doi-asserted-by":"crossref","first-page":"2265","DOI":"10.1002\/(SICI)1097-0258(19981015)17:19<2265::AID-SIM918>3.0.CO;2-B","article-title":"Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group","volume":"17","author":"D\u2019Agostino","year":"1998","journal-title":"Stat Med"},{"key":"R13-14-20260130","doi-asserted-by":"crossref","first-page":"11","DOI":"10.2165\/00148365-200605010-00003","article-title":"Methodological aspects in the assessment of treatment effects in observational health outcomes studies","volume":"5","author":"Haro","year":"2006","journal-title":"Appl Health Econ Health Policy"},{"key":"R14-14-20260130","first-page":"293","article-title":"Thymoglobulin induction in living donor renal transplant recipients: Report from TAILOR registry","volume":"6","author":"Gaber","year":"2006","journal-title":"Am J Transplant"},{"key":"R15-14-20260130","first-page":"208","article-title":"An introduction to matching and its applications using SAS.","volume":"29","author":"Mandrekar","year":"2004","journal-title":"Proceedings of the 2th Annual SAS Users Group International (SUGI) Conference"},{"key":"R16-14-20260130","first-page":"331","article-title":"Software for optimal matching in observational studies","volume":"7","author":"Bergstralh","year":"1996","journal-title":"Epidemiology"},{"key":"R18-14-20260130","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1097\/01.TP.0000134399.10352.E4","article-title":"The selective use of basiliximab versus thymoglobulin in combination with sirolimus for cadaveric renal transplant recipients at low risk versus high risk for delayed graft function","volume":"78","author":"Knight","year":"2004","journal-title":"Transplantation"},{"key":"R19-14-20260130","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1097\/00007890-199912270-00009","article-title":"Prednisone withdrawal in kidney transplant recipients on cyclosporine and mycophenolate mofetil\u2014A prospective randomized study. Steroid Withdrawal Study Group","volume":"68","author":"Ahsan","year":"1999","journal-title":"Transplantation"},{"key":"R20-14-20260130","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1097\/00007890-200011150-00015","article-title":"Double-blind comparison of two corticosteroid regimens plus mycophenolate mofetil and cyclosporine for prevention of acute renal allograft rejection","volume":"70","author":"Vanrenterghem","year":"2000","journal-title":"Transplantation"},{"key":"R21-14-20260130","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1681\/ASN.V11101910","article-title":"A meta-analysis of immunosuppression withdrawal trials in renal transplantation","volume":"11","author":"Kasiske","year":"2000","journal-title":"J Am Soc Nephrol"},{"key":"R22-14-20260130","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1097\/01.TP.0000173824.22834.A1","article-title":"Recipient age and mycophenolate mofetil as the main determinants of outcome after steroid withdrawal: Analysis of long-term follow-up in renal transplantation","volume":"80","author":"Laouad","year":"2005","journal-title":"Transplantation"},{"key":"R23-14-20260130","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1111\/j.1399-3046.2005.00319.x","article-title":"Early discontinuation of steroids is safe and effective in pediatric kidney transplant recipients","volume":"9","author":"Oberholzer","year":"2005","journal-title":"Pediatr Transplant"},{"key":"R24-14-20260130","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1111\/j.1600-6143.2004.00655.x","article-title":"A multicenter pilot study of early (4-day) steroid cessation in renal transplant recipients under simulect, tacrolimus and sirolimus","volume":"5","author":"Woodle","year":"2005","journal-title":"Am J Transplant"},{"key":"R25-14-20260130","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1111\/j.1600-6143.2007.02057.x","article-title":"A randomized, multicenter study of steroid avoidance, early steroid withdrawal or standard steroid therapy in kidney transplant recipients","volume":"8","author":"Vincenti","year":"2008","journal-title":"Am J Transplant"},{"key":"R26-14-20260130","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1016\/j.transproceed.2006.02.116","article-title":"Acute rejection risk in kidney transplant recipients on steroid-avoidance immunosuppression receiving induction with either antithymocyte globulin or basiliximab","volume":"38","author":"Heilman","year":"2006","journal-title":"Transplant Proc"},{"key":"R27-14-20260130","doi-asserted-by":"crossref","first-page":"2299","DOI":"10.1681\/ASN.2006030258","article-title":"Agreement of immunosuppression regimens described in Medicare pharmacy claims with the Organ Procurement and Transplantation Network survey","volume":"17","author":"Stirnemann","year":"2006","journal-title":"J Am Soc Nephrol"},{"key":"R28-14-20260130","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1097\/MLR.0b013e3180326121","article-title":"Linking the US transplant registry to administrative claims data: Expanding the potential of transplant research","volume":"45","author":"Gilmore","year":"2007","journal-title":"Med Care"},{"key":"R29-14-20260130","doi-asserted-by":"crossref","first-page":"117","DOI":"10.2215\/CJN.02790707","article-title":"Novel methods for tracking long-term maintenance immunosuppression regimens","volume":"3","author":"Buchanan","year":"2008","journal-title":"Clin J Am Soc Nephrol"}],"container-title":["Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00007890-200905270-00014","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T13:01:15Z","timestamp":1769778075000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00007890-200905270-00014"}},"subtitle":["Application of Statistical Approaches to Reduce Bias in Observational Comparisons"],"short-title":[],"issued":{"date-parts":[[2009,5,27]]},"references-count":27,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2009]]}},"URL":"https:\/\/doi.org\/10.1097\/tp.0b013e3181a484d7","relation":{},"ISSN":["0041-1337"],"issn-type":[{"value":"0041-1337","type":"print"}],"subject":[],"published":{"date-parts":[[2009,5,27]]}}}